Cardiovascular disease is the leading cause of death for women, and the risk profile changes sharply around menopause. Before menopause, women have a documented cardiovascular advantage over men of the same age, largely attributed to estrogen’s protective effects on blood vessels and lipid metabolism. That advantage narrows and then disappears after menopause, when postmenopausal women’s cardiovascular disease risk rises to approach or exceed that of men in the same age range. This shift is a major reason growing numbers of women are researching nattokinase, a fibrinolytic enzyme studied for its effects on blood clotting factors and circulation, specifically in the context of post-menopausal cardiovascular support.
Key Takeaways
- Estrogen has documented protective effects on blood vessels, lipid profiles, and inflammation; its decline after menopause is directly linked to rising cardiovascular risk in women.
- Postmenopausal women’s cardiovascular disease risk rises to approach that of age-matched men, a pattern attributed largely to the loss of estrogen’s protective effects.
- Nattokinase has been studied for effects on blood pressure and clotting-related markers, with several clinical trials including substantial proportions of female participants.
- Some research suggests nattokinase may affect certain clotting-related markers differently in women than in men, though this specific finding needs more independent, peer-reviewed confirmation.
- Nattokinase is not a replacement for hormone therapy or established cardiovascular risk management, it should be discussed with a physician alongside a woman’s full menopausal and cardiovascular care plan.
Why Cardiovascular Risk Changes So Sharply at Menopause
Before menopause, estrogen provides measurable protection against cardiovascular disease through several mechanisms: it promotes vasodilation (helping blood vessels relax and stay flexible), reduces vascular inflammation, and supports a more favorable lipid profile. Research on the biology of estrogen’s cardiovascular effects, including work examining oxidative stress pathways, has documented these protective mechanisms in detail.
When estrogen production drops sharply at menopause, these protective effects fade. Postmenopausal women experience changes including reduced arterial elasticity, increased blood pressure, shifts in lipid profiles, and altered clotting factor activity. Multiple studies tracking cardiovascular risk factors across the menopausal transition describe measurable changes in vascular stiffness and metabolic markers during this period, consistent with the sharp rise in cardiovascular disease incidence seen in women after menopause.
Where Nattokinase Research Intersects With This Population
Nattokinase has been studied primarily for two cardiovascular-relevant effects: breaking down fibrin (a protein central to blood clot structure) and lowering blood pressure by a few mmHg in a few small trials (the evidence is mixed, and a 3-year trial in 265 healthy adults found no effect on blood pressure) [1][2].[1] A systematic review and meta-analysis of randomized controlled trials on nattokinase and blood pressure found a meaningful proportion of the pooled study population were women, meaning existing blood pressure evidence for nattokinase already substantially reflects female physiology, even though the trials were not designed as sex-specific studies.
Research note: A Health Canada licence for a nattokinase capsule advises against use in pregnancy or breastfeeding [6].
Separately, some research has examined whether nattokinase affects clotting-related markers differently by sex. One report describes a trial finding a reduction in von Willebrand factor, a protein involved in clot formation and associated with cardiovascular risk, observed specifically in female participants and not in male participants in that same trial. This is a genuinely interesting signal, but it should be treated cautiously: the finding has circulated primarily through commercial and blog sources rather than being independently confirmed across multiple peer-reviewed studies, so it represents a preliminary lead rather than an established sex-specific effect.
The von Willebrand factor result is itself weak. In the placebo-controlled trial of 79 adults that reported a 15% reduction, the between-group difference at 8 weeks was only a statistical trend, and a separate 3-year trial in 265 healthy adults found no effect of nattokinase on von Willebrand factor [3][1][2].
What This Does and Does Not Mean for Postmenopausal Women
It is important to be precise about what the current evidence supports. Nattokinase has not been studied as a treatment for menopause-related cardiovascular risk specifically, and it is not a substitute for evidence-based approaches to postmenopausal cardiovascular care, which may include lifestyle modification, statins or other lipid-lowering therapy when indicated, blood pressure management, and, for some women, hormone therapy discussed with a physician. What the existing research does suggest is that nattokinase’s studied effects on blood pressure and fibrin-related markers touch the same cardiovascular risk factors that shift unfavorably after menopause (the trial results are mixed, with no blood pressure effect in a 3-year trial of 265 healthy adults) [2][3], which is the mechanistic reason interest in nattokinase has grown among this population, even without a dedicated menopause-specific trial.
Bone Health: A Related but Separate Consideration
Natto, the fermented food nattokinase is derived from, also contains vitamin K2 (specifically the MK-7 form), which is separate from the nattokinase enzyme itself but often discussed alongside it because both come from the same food source. Vitamin K2 has been studied for its role in bone metabolism, and a multi-year trial found MK-7 supplementation reduced bone loss in postmenopausal women, with protective effects becoming more apparent after the second year. It is worth noting explicitly that most nattokinase supplements, including NSK-SD-based products, are specifically processed to remove vitamin K2, because vitamin K2 can interfere with warfarin therapy (EFSA notes it is removed during NSK-SD manufacture) [4][5]. If bone health from vitamin K2 is a specific goal, that requires a separate vitamin K2 supplement, not a standard nattokinase product.
Practical Considerations for Postmenopausal Women Considering Nattokinase
If you are postmenopausal and considering nattokinase for cardiovascular support, bring it up with your physician as part of your broader cardiovascular risk conversation, not as a standalone decision. This is especially important if you are on hormone therapy, a statin, a blood thinner, or an antiplatelet medication, or if you have any personal or family history of bleeding disorders, stroke, or clotting events. Nattokinase’s fibrinolytic and antiplatelet activity means the same bleeding-risk cautions that apply to any user apply to postmenopausal women as well, and in some cases postmenopausal women are more likely to also be on cardiovascular medications where those interactions matter most.
A Note on the Evidence
No large-scale, dedicated clinical trial has evaluated nattokinase specifically as an intervention for postmenopausal cardiovascular risk; much of the current supporting evidence is drawn from broader nattokinase trials with substantial female representation, mechanistic research on estrogen and cardiovascular health, and preliminary sex-differentiated findings that have not been independently confirmed in the peer-reviewed literature. This is educational information, not medical advice. Postmenopausal women, and especially those on hormone therapy or cardiovascular medications, should consult their physician before starting nattokinase.
Frequently Asked Questions
Why are postmenopausal women specifically interested in nattokinase?
Cardiovascular disease risk rises sharply after menopause as estrogen’s protective effects on blood vessels, lipids, and inflammation decline. Nattokinase has been studied for effects on blood pressure and fibrin-related clotting markers, the same risk factors affected by estrogen loss, which is why interest has grown in this population, even without a dedicated menopause-specific trial.
Does nattokinase replace hormone therapy for cardiovascular protection?
No. Nattokinase has not been studied as a replacement for hormone therapy or other evidence-based postmenopausal cardiovascular care. It should be discussed with a physician as a potential addition to, not a substitute for, an established cardiovascular risk management plan.
Does nattokinase affect women and men differently?
Some preliminary research suggests possible sex-differentiated effects on certain clotting markers, but this finding has not been independently confirmed across multiple peer-reviewed studies and should be treated as a preliminary lead rather than an established fact.
Does nattokinase help with bone health after menopause?
Not directly. The vitamin K2 in natto (not nattokinase itself) has been studied for bone benefits, but most nattokinase supplements specifically remove vitamin K2 because it works against the enzyme’s fibrinolytic purpose. Bone-health benefits from vitamin K2 require a separate supplement.
References
- Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine (2023). PMID 39076715
- Hodis HN et al. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical hemorheology and microcirculation (2021). PMID 33843667
- Jensen GS et al. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integrated blood pressure control (2016). PMID 27785095
- Schurgers LJ et al. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood (2007). PMID 17158229
- European Food Safety Authority (EFSA NDA Panel) Safety of fermented soybean extract NSK-SD as a novel food pursuant to Regulation (EC) No 258/97. European Food Safety Authority (EFSA NDA Panel) (2016). source
- Health Canada Licensed Natural Health Product NPN 80089299: Nattokinase 100 mg. Health Canada (2026). source
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
